Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_3
1
14%
Ph phase_4
1
14%
Ph phase_1
3
43%

Phase Distribution

3

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)
Other(3)

Detailed Status

unknown3
Not yet recruiting2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (42.9%)
Phase 22 (28.6%)
Phase 31 (14.3%)
Phase 41 (14.3%)

Trials by Status

completed114%
not_yet_recruiting229%
terminated114%
unknown343%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

NCT02621333
unknownphase_2

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

NCT03146637
unknownphase_1

Safety and Efficacy of γδ T Cell Against Gastric Cancer

NCT02585908
completedphase_1

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

NCT01894373
unknownphase_3

Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC

NCT02568748
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02621333Phase 2

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Terminated
NCT03146637Phase 2

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Unknown
NCT02585908Phase 1

Safety and Efficacy of γδ T Cell Against Gastric Cancer

Unknown
NCT01894373Phase 1

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

Completed
NCT02568748Phase 3

Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC

Unknown
NCT02496988Phase 4

Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas

Not Yet Recruiting
NCT02494804Phase 1

Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas

Not Yet Recruiting

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7